Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
IBS-C Drug market report explains the definition, types, applications, major countries, and major players of the IBS-C Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Novartis Pharma
Salix Pharmaceuticals
Albireo Pharma
Ardelyx
Ono Pharmaceutical
Actavis Nordic
Synthetic Biologics
The Menarini Group
Astellas Pharmaceuticals
Teva Pharmaceutical Industries
Nestle
Bama-Geve
Abbott Laboratories
Yuhan Corp
Norgine
Synergy Pharmaceuticals
Ferring BV
Catalent Pharmaceuticals Solutions
Sucampo Pharmaceuticals
Prometheus Laboratories
Ironwood Pharmaceuticals
Astrazeneca
By Type:
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
By End-User:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global IBS-C Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 IBS-C Drug Outlook to 2028- Original Forecasts
-
2.2 IBS-C Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term IBS-C Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global IBS-C Drug Market- Recent Developments
-
6.1 IBS-C Drug Market News and Developments
-
6.2 IBS-C Drug Market Deals Landscape
7 IBS-C Drug Raw Materials and Cost Structure Analysis
-
7.1 IBS-C Drug Key Raw Materials
-
7.2 IBS-C Drug Price Trend of Key Raw Materials
-
7.3 IBS-C Drug Key Suppliers of Raw Materials
-
7.4 IBS-C Drug Market Concentration Rate of Raw Materials
-
7.5 IBS-C Drug Cost Structure Analysis
-
7.5.1 IBS-C Drug Raw Materials Analysis
-
7.5.2 IBS-C Drug Labor Cost Analysis
-
7.5.3 IBS-C Drug Manufacturing Expenses Analysis
8 Global IBS-C Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global IBS-C Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global IBS-C Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global IBS-C Drug Market Outlook by Types and Applications to 2022
-
9.1 Global IBS-C Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Linaclotide Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Lubiprostone Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Osmotic Laxatives Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Stimulant Laxatives Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global IBS-C Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)
10 Region and Country-wise IBS-C Drug Market Analysis and Outlook till 2022
-
10.1 Global IBS-C Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States IBS-C Drug Consumption (2017-2022)
-
10.2.2 Canada IBS-C Drug Consumption (2017-2022)
-
10.2.3 Mexico IBS-C Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany IBS-C Drug Consumption (2017-2022)
-
10.3.2 UK IBS-C Drug Consumption (2017-2022)
-
10.3.3 Spain IBS-C Drug Consumption (2017-2022)
-
10.3.4 Belgium IBS-C Drug Consumption (2017-2022)
-
10.3.5 France IBS-C Drug Consumption (2017-2022)
-
10.3.6 Italy IBS-C Drug Consumption (2017-2022)
-
10.3.7 Denmark IBS-C Drug Consumption (2017-2022)
-
10.3.8 Finland IBS-C Drug Consumption (2017-2022)
-
10.3.9 Norway IBS-C Drug Consumption (2017-2022)
-
10.3.10 Sweden IBS-C Drug Consumption (2017-2022)
-
10.3.11 Poland IBS-C Drug Consumption (2017-2022)
-
10.3.12 Russia IBS-C Drug Consumption (2017-2022)
-
10.3.13 Turkey IBS-C Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China IBS-C Drug Consumption (2017-2022)
-
10.4.2 Japan IBS-C Drug Consumption (2017-2022)
-
10.4.3 India IBS-C Drug Consumption (2017-2022)
-
10.4.4 South Korea IBS-C Drug Consumption (2017-2022)
-
10.4.5 Pakistan IBS-C Drug Consumption (2017-2022)
-
10.4.6 Bangladesh IBS-C Drug Consumption (2017-2022)
-
10.4.7 Indonesia IBS-C Drug Consumption (2017-2022)
-
10.4.8 Thailand IBS-C Drug Consumption (2017-2022)
-
10.4.9 Singapore IBS-C Drug Consumption (2017-2022)
-
10.4.10 Malaysia IBS-C Drug Consumption (2017-2022)
-
10.4.11 Philippines IBS-C Drug Consumption (2017-2022)
-
10.4.12 Vietnam IBS-C Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil IBS-C Drug Consumption (2017-2022)
-
10.5.2 Colombia IBS-C Drug Consumption (2017-2022)
-
10.5.3 Chile IBS-C Drug Consumption (2017-2022)
-
10.5.4 Argentina IBS-C Drug Consumption (2017-2022)
-
10.5.5 Venezuela IBS-C Drug Consumption (2017-2022)
-
10.5.6 Peru IBS-C Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico IBS-C Drug Consumption (2017-2022)
-
10.5.8 Ecuador IBS-C Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain IBS-C Drug Consumption (2017-2022)
-
10.6.2 Kuwait IBS-C Drug Consumption (2017-2022)
-
10.6.3 Oman IBS-C Drug Consumption (2017-2022)
-
10.6.4 Qatar IBS-C Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia IBS-C Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates IBS-C Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria IBS-C Drug Consumption (2017-2022)
-
10.7.2 South Africa IBS-C Drug Consumption (2017-2022)
-
10.7.3 Egypt IBS-C Drug Consumption (2017-2022)
-
10.7.4 Algeria IBS-C Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia IBS-C Drug Consumption (2017-2022)
-
10.8.2 New Zealand IBS-C Drug Consumption (2017-2022)
11 Global IBS-C Drug Competitive Analysis
-
11.1 Novartis Pharma
-
11.1.1 Novartis Pharma Company Details
-
11.1.2 Novartis Pharma IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Novartis Pharma IBS-C Drug Main Business and Markets Served
-
11.1.4 Novartis Pharma IBS-C Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Salix Pharmaceuticals
-
11.2.1 Salix Pharmaceuticals Company Details
-
11.2.2 Salix Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Salix Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
11.2.4 Salix Pharmaceuticals IBS-C Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Albireo Pharma
-
11.3.1 Albireo Pharma Company Details
-
11.3.2 Albireo Pharma IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Albireo Pharma IBS-C Drug Main Business and Markets Served
-
11.3.4 Albireo Pharma IBS-C Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Ardelyx
-
11.4.1 Ardelyx Company Details
-
11.4.2 Ardelyx IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Ardelyx IBS-C Drug Main Business and Markets Served
-
11.4.4 Ardelyx IBS-C Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Ono Pharmaceutical
-
11.5.1 Ono Pharmaceutical Company Details
-
11.5.2 Ono Pharmaceutical IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Ono Pharmaceutical IBS-C Drug Main Business and Markets Served
-
11.5.4 Ono Pharmaceutical IBS-C Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Actavis Nordic
-
11.6.1 Actavis Nordic Company Details
-
11.6.2 Actavis Nordic IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Actavis Nordic IBS-C Drug Main Business and Markets Served
-
11.6.4 Actavis Nordic IBS-C Drug Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Synthetic Biologics
-
11.7.1 Synthetic Biologics Company Details
-
11.7.2 Synthetic Biologics IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Synthetic Biologics IBS-C Drug Main Business and Markets Served
-
11.7.4 Synthetic Biologics IBS-C Drug Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 The Menarini Group
-
11.8.1 The Menarini Group Company Details
-
11.8.2 The Menarini Group IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 The Menarini Group IBS-C Drug Main Business and Markets Served
-
11.8.4 The Menarini Group IBS-C Drug Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Astellas Pharmaceuticals
-
11.9.1 Astellas Pharmaceuticals Company Details
-
11.9.2 Astellas Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Astellas Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
11.9.4 Astellas Pharmaceuticals IBS-C Drug Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Teva Pharmaceutical Industries
-
11.10.1 Teva Pharmaceutical Industries Company Details
-
11.10.2 Teva Pharmaceutical Industries IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Teva Pharmaceutical Industries IBS-C Drug Main Business and Markets Served
-
11.10.4 Teva Pharmaceutical Industries IBS-C Drug Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Nestle
-
11.11.1 Nestle Company Details
-
11.11.2 Nestle IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Nestle IBS-C Drug Main Business and Markets Served
-
11.11.4 Nestle IBS-C Drug Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Bama-Geve
-
11.12.1 Bama-Geve Company Details
-
11.12.2 Bama-Geve IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Bama-Geve IBS-C Drug Main Business and Markets Served
-
11.12.4 Bama-Geve IBS-C Drug Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Abbott Laboratories
-
11.13.1 Abbott Laboratories Company Details
-
11.13.2 Abbott Laboratories IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Abbott Laboratories IBS-C Drug Main Business and Markets Served
-
11.13.4 Abbott Laboratories IBS-C Drug Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Yuhan Corp
-
11.14.1 Yuhan Corp Company Details
-
11.14.2 Yuhan Corp IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Yuhan Corp IBS-C Drug Main Business and Markets Served
-
11.14.4 Yuhan Corp IBS-C Drug Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Norgine
-
11.15.1 Norgine Company Details
-
11.15.2 Norgine IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Norgine IBS-C Drug Main Business and Markets Served
-
11.15.4 Norgine IBS-C Drug Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Synergy Pharmaceuticals
-
11.16.1 Synergy Pharmaceuticals Company Details
-
11.16.2 Synergy Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Synergy Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
11.16.4 Synergy Pharmaceuticals IBS-C Drug Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Ferring BV
-
11.17.1 Ferring BV Company Details
-
11.17.2 Ferring BV IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Ferring BV IBS-C Drug Main Business and Markets Served
-
11.17.4 Ferring BV IBS-C Drug Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 Catalent Pharmaceuticals Solutions
-
11.18.1 Catalent Pharmaceuticals Solutions Company Details
-
11.18.2 Catalent Pharmaceuticals Solutions IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 Catalent Pharmaceuticals Solutions IBS-C Drug Main Business and Markets Served
-
11.18.4 Catalent Pharmaceuticals Solutions IBS-C Drug Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Sucampo Pharmaceuticals
-
11.19.1 Sucampo Pharmaceuticals Company Details
-
11.19.2 Sucampo Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Sucampo Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
11.19.4 Sucampo Pharmaceuticals IBS-C Drug Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Prometheus Laboratories
-
11.20.1 Prometheus Laboratories Company Details
-
11.20.2 Prometheus Laboratories IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Prometheus Laboratories IBS-C Drug Main Business and Markets Served
-
11.20.4 Prometheus Laboratories IBS-C Drug Product Portfolio
-
11.20.5 Recent Research and Development Strategies
-
11.21 Ironwood Pharmaceuticals
-
11.21.1 Ironwood Pharmaceuticals Company Details
-
11.21.2 Ironwood Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.21.3 Ironwood Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
11.21.4 Ironwood Pharmaceuticals IBS-C Drug Product Portfolio
-
11.21.5 Recent Research and Development Strategies
-
11.22 Astrazeneca
-
11.22.1 Astrazeneca Company Details
-
11.22.2 Astrazeneca IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.22.3 Astrazeneca IBS-C Drug Main Business and Markets Served
-
11.22.4 Astrazeneca IBS-C Drug Product Portfolio
-
11.22.5 Recent Research and Development Strategies
12 Global IBS-C Drug Market Outlook by Types and Applications to 2028
-
12.1 Global IBS-C Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Linaclotide Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Lubiprostone Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Osmotic Laxatives Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Stimulant Laxatives Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global IBS-C Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise IBS-C Drug Market Analysis and Outlook to 2028
-
13.1 Global IBS-C Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States IBS-C Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada IBS-C Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico IBS-C Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.2 UK IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.5 France IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia IBS-C Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey IBS-C Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.3 India IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines IBS-C Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam IBS-C Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil IBS-C Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia IBS-C Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile IBS-C Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina IBS-C Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela IBS-C Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru IBS-C Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico IBS-C Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador IBS-C Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain IBS-C Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait IBS-C Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman IBS-C Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar IBS-C Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia IBS-C Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates IBS-C Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria IBS-C Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa IBS-C Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt IBS-C Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria IBS-C Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia IBS-C Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand IBS-C Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of IBS-C Drug
-
Figure of IBS-C Drug Picture
-
Table Global IBS-C Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global IBS-C Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Linaclotide Consumption and Growth Rate (2017-2022)
-
Figure Global Lubiprostone Consumption and Growth Rate (2017-2022)
-
Figure Global Osmotic Laxatives Consumption and Growth Rate (2017-2022)
-
Figure Global Stimulant Laxatives Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global IBS-C Drug Consumption by Country (2017-2022)
-
Table North America IBS-C Drug Consumption by Country (2017-2022)
-
Figure United States IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Table Europe IBS-C Drug Consumption by Country (2017-2022)
-
Figure Germany IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure UK IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure France IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Table APAC IBS-C Drug Consumption by Country (2017-2022)
-
Figure China IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure India IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Table South America IBS-C Drug Consumption by Country (2017-2022)
-
Figure Brazil IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Table GCC IBS-C Drug Consumption by Country (2017-2022)
-
Figure Bahrain IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Table Africa IBS-C Drug Consumption by Country (2017-2022)
-
Figure Nigeria IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania IBS-C Drug Consumption by Country (2017-2022)
-
Figure Australia IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand IBS-C Drug Consumption and Growth Rate (2017-2022)
-
Table Novartis Pharma Company Details
-
Table Novartis Pharma IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Pharma IBS-C Drug Main Business and Markets Served
-
Table Novartis Pharma IBS-C Drug Product Portfolio
-
Table Salix Pharmaceuticals Company Details
-
Table Salix Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Salix Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
Table Salix Pharmaceuticals IBS-C Drug Product Portfolio
-
Table Albireo Pharma Company Details
-
Table Albireo Pharma IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Albireo Pharma IBS-C Drug Main Business and Markets Served
-
Table Albireo Pharma IBS-C Drug Product Portfolio
-
Table Ardelyx Company Details
-
Table Ardelyx IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ardelyx IBS-C Drug Main Business and Markets Served
-
Table Ardelyx IBS-C Drug Product Portfolio
-
Table Ono Pharmaceutical Company Details
-
Table Ono Pharmaceutical IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ono Pharmaceutical IBS-C Drug Main Business and Markets Served
-
Table Ono Pharmaceutical IBS-C Drug Product Portfolio
-
Table Actavis Nordic Company Details
-
Table Actavis Nordic IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Actavis Nordic IBS-C Drug Main Business and Markets Served
-
Table Actavis Nordic IBS-C Drug Product Portfolio
-
Table Synthetic Biologics Company Details
-
Table Synthetic Biologics IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Synthetic Biologics IBS-C Drug Main Business and Markets Served
-
Table Synthetic Biologics IBS-C Drug Product Portfolio
-
Table The Menarini Group Company Details
-
Table The Menarini Group IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table The Menarini Group IBS-C Drug Main Business and Markets Served
-
Table The Menarini Group IBS-C Drug Product Portfolio
-
Table Astellas Pharmaceuticals Company Details
-
Table Astellas Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
Table Astellas Pharmaceuticals IBS-C Drug Product Portfolio
-
Table Teva Pharmaceutical Industries Company Details
-
Table Teva Pharmaceutical Industries IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries IBS-C Drug Main Business and Markets Served
-
Table Teva Pharmaceutical Industries IBS-C Drug Product Portfolio
-
Table Nestle Company Details
-
Table Nestle IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Nestle IBS-C Drug Main Business and Markets Served
-
Table Nestle IBS-C Drug Product Portfolio
-
Table Bama-Geve Company Details
-
Table Bama-Geve IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bama-Geve IBS-C Drug Main Business and Markets Served
-
Table Bama-Geve IBS-C Drug Product Portfolio
-
Table Abbott Laboratories Company Details
-
Table Abbott Laboratories IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Laboratories IBS-C Drug Main Business and Markets Served
-
Table Abbott Laboratories IBS-C Drug Product Portfolio
-
Table Yuhan Corp Company Details
-
Table Yuhan Corp IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Yuhan Corp IBS-C Drug Main Business and Markets Served
-
Table Yuhan Corp IBS-C Drug Product Portfolio
-
Table Norgine Company Details
-
Table Norgine IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Norgine IBS-C Drug Main Business and Markets Served
-
Table Norgine IBS-C Drug Product Portfolio
-
Table Synergy Pharmaceuticals Company Details
-
Table Synergy Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Synergy Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
Table Synergy Pharmaceuticals IBS-C Drug Product Portfolio
-
Table Ferring BV Company Details
-
Table Ferring BV IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ferring BV IBS-C Drug Main Business and Markets Served
-
Table Ferring BV IBS-C Drug Product Portfolio
-
Table Catalent Pharmaceuticals Solutions Company Details
-
Table Catalent Pharmaceuticals Solutions IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Catalent Pharmaceuticals Solutions IBS-C Drug Main Business and Markets Served
-
Table Catalent Pharmaceuticals Solutions IBS-C Drug Product Portfolio
-
Table Sucampo Pharmaceuticals Company Details
-
Table Sucampo Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sucampo Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
Table Sucampo Pharmaceuticals IBS-C Drug Product Portfolio
-
Table Prometheus Laboratories Company Details
-
Table Prometheus Laboratories IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Prometheus Laboratories IBS-C Drug Main Business and Markets Served
-
Table Prometheus Laboratories IBS-C Drug Product Portfolio
-
Table Ironwood Pharmaceuticals Company Details
-
Table Ironwood Pharmaceuticals IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ironwood Pharmaceuticals IBS-C Drug Main Business and Markets Served
-
Table Ironwood Pharmaceuticals IBS-C Drug Product Portfolio
-
Table Astrazeneca Company Details
-
Table Astrazeneca IBS-C Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astrazeneca IBS-C Drug Main Business and Markets Served
-
Table Astrazeneca IBS-C Drug Product Portfolio
-
Figure Global Linaclotide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lubiprostone Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Osmotic Laxatives Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Stimulant Laxatives Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global IBS-C Drug Consumption Forecast by Country (2022-2028)
-
Table North America IBS-C Drug Consumption Forecast by Country (2022-2028)
-
Figure United States IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe IBS-C Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC IBS-C Drug Consumption Forecast by Country (2022-2028)
-
Figure China IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America IBS-C Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC IBS-C Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa IBS-C Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania IBS-C Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)
-
